QIAGEN Oncohematology Research with ipsogen

Major advancements in hematological cancer research were made by the discovery of disease-specific molecular markers. Take those advancements further with precise and accurate detection assays and easier workflows using biomarker testing solutions from ipsogen.

Our continuously expanding range of leukemia biomarker assays now includes a ready-to-use kit for the detection of somatic mutations in exon 9 of the CALR gene! The CALR RGQ PCR Kit enables specific and simultaneous identification of the two main CALR mutations (Type 1 & Type 2) and detection of additional minor variants in CALR exon 9, all in a single PCR run.

1

CALR RGQ PCR Kit RUO

  • CALR is a new cancer biomarker that is mutated in the majority of JAK2 V617F negative cases of Myeloproliferative Neoplasms (MPN), a major form of leukemia.
  • CALR mutations in MPN were just recently discovered in late 2013, but since then there has been increasing evidence for the relevance of CALR in MPN, and its role in MPN subtypes.
  • Currently there is ongoing research for optimized testing algorithms in MPNs using the most relevant molecular markers JAK2 V617F, CALR and MPL. However, CALR research today is usually performed by cumbersome laboratory developed tests (LDTs) using fragment size analysis followed by Sanger sequencing. Lack of a commercially available kit has led to limited CALR research.
Discover QIAGEN’s CALR Kit

Contact us for more information:

Click to discover complete range of ipsogen blood cancer biomarker solution products:

All ipsogen products mentioned here are intended for research use only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention, or treatment of a disease.

Contribute to advancements in oncohematology research by using the new CALR RGQ PCR Kit and other biomarker solutions from ipsogen.

Myeloproliferative neoplasms (MPN) represent 30% of hematological malignancies. JAK2 V617F and CALR biomarkers are highly relevant to advancing MPN research, and were both included in the 2016 WHO guidelines (6).

MPNs are characterized by accumulation of different cell types in blood, which are either Ph-positive (Ph+) or Ph-negative (Ph-), indicating the presence or absence of the “Philadelphia chromosome” rearrangement ( 1, 2). The JAK2 V617F somatic mutation in the Janus tyrosine kinase 2 (JAK2) gene is characteristic of Ph- MPN, and is highly prevalent in multiple MPN subtypes (3,  4).

The recent discovery of somatic mutations in the endoplasmic reticulum chaperone CALR (calreticulin) in MPN Ph- cases has led to advances in research and characterization of this new biomarker (3, 5). A total of 36 insertions or deletions were initially described for CALR (2), and somatic insertions or deletions in exon 9 of this gene have been found in a majority of non-mutated JAK2 V617F MPN cases (Figure 1). The findings support the significance of CALR to advance MPN research.

1. Barbui, T. et al. (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 5, e337; doi:10.1038/bcj.2015.64.

2. Langabeer, S.E. et al. (2015) Molecular diagnostics of myeloproliferative neoplasms. Eur. J. Haematol. 95:270; doi: 10.1111/ejh.12578.

3. Kampfl, T. et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. NEJM 369:2379;doi: 10.1056/NEJMoa1311347.

4. Titmarsh, G.J. et al. (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Hematol. 89:581;doi:10.1002/ajh.23690.

5. Nangalia et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. NEJM; doi: 10.1056/NEJMoa1312542.

6. Arber D.A. et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391;doi: 10.1182/blood-2016-03-643544.

chart